Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael Koren, Kayvon Modjarrad, Erica L Sondergaard et al.|The Lancet Infectious Diseases|2023Cited by 23
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trialKayvon Modjarrad, Emmanuel Feroldi, Paul T. Scott et al.|The Lancet Infectious Diseases|2024Cited by 8
Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Humans is Diminished by Priming with a Yellow Fever or Japanese Encephalitis Virus Vaccine: Elucidating Immunologic Interference between Flavivirus VaccinesKayvon Modjarrad, Nelson L. Michael, Michael Koren et al.|The Journal of Immunology|2020Cited by 1